

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES,
CANADA, AUSTRALIA OR JAPAN**

Announcement no. 10/2007

To the Copenhagen Stock Exchange and the press.

Copenhagen, June 4, 2007

**Major shareholders announcement pursuant to section 29 of the Danish Securities
Trading Act**

Following Exiqon's issuance of new shares, Scandinavian Life Science Venture's shareholding in Exiqon A/S now amounts to 9.6 % of which 4.8% are owned by Medicon Valley Capital K/S and 4.8% are held by Medicon Valley Capital KB cf. section 1 (2) of executive order no 728 of 11 June 2005 about major shareholders.

For additional information please contact

Lars Kongsbak, CEO, tel +45 4566 0888 or +45 4090 2101

Hans Henrik Chrois Christensen, CFO +45 4565 0953 or +45 4090 2131

Exiqon is a biotechnology company engaged in the development, manufacture and marketing of products for genetic analysis.

Exiqon is witnessing strong growth and is one of the innovative leaders in the segments we have selected. We sell our products to a rapidly growing number of scientists in the pharmaceutical industry and in research laboratories around the world. These products include reagents and kits which in a precise and sensitive manner translate the information in the genes into the answers sought by the scientists and the industry.

Exiqon's products build on the company's patented Locked Nucleic Acid (LNA™) technology. We expect to further develop our existing products and technologies so that we can deliver future solutions to important challenges in the field of molecular diagnostics.

Exiqon's products are marketed through its own sales organisation and through license and distribution agreements with recognised partners, including Roche Diagnostics and Luminex